Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZVRA
stocks logo

ZVRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
28.05M
+132.94%
0.050
-107.25%
32.25M
+58.09%
0.104
-273.33%
35.47M
+37.05%
0.144
-88.1%
Estimates Revision
The market is revising No Change the revenue expectations for Zevra Therapeutics, Inc. (ZVRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -3.24%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.89%
In Past 3 Month
Stock Price
Go Down
down Image
-3.24%
In Past 3 Month
Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24.00 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24.00 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.660
sliders
Low
21.00
Averages
24.00
High
26.00
Current: 8.660
sliders
Low
21.00
Averages
24.00
High
26.00
Canaccord
Buy
downgrade
$25 -> $24
2025-11-06
Reason
Canaccord
Price Target
$25 -> $24
2025-11-06
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Zevra Therapeutics to $24 from $25 and keeps a Buy rating on the shares. The firm lowered its target on a softening Europe Miplyffa ramp.
Cantor Fitzgerald
Kristen Kluska
Overweight
downgrade
$29 -> $24
2025-11-06
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$29 -> $24
2025-11-06
downgrade
Overweight
Reason
Cantor Fitzgerald analyst Kristen Kluska lowered the firm's price target on Zevra Therapeutics to $24 from $29 and keeps an Overweight rating on the shares.
Citizens JMP
Jason Butler
Outperform
downgrade
$19 -> $18
2025-08-13
Reason
Citizens JMP
Jason Butler
Price Target
$19 -> $18
2025-08-13
downgrade
Outperform
Reason
Citizens JMP analyst Jason Butler lowered the firm's price target on Zevra Therapeutics to $18 from $19 and keeps an Outperform rating on the shares. The MIPLYFFA launch continues to outpace expectations, with Q2 U.S. sales of $21.5M, exceeding expectations, with management noting that there have been 129 total patient enrollment forms received to date, up 7 from 122 at the end of March, the analyst tells investors in a research note. Zevra is well-funded to achieve positive cash flow, the firm adds.
Cantor Fitzgerald
NULL -> Overweight
maintain
$25 -> $29
2025-07-10
Reason
Cantor Fitzgerald
Price Target
$25 -> $29
2025-07-10
maintain
NULL -> Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Zevra Therapeutics to $29 from $25 and keeps an Overweight rating on the shares. Miplyffa stands a good chance of approval in the EU, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
initiated
$26
2025-07-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$26
2025-07-02
initiated
Reason
H.C. Wainwright initiated coverage of Zevra Therapeutics with a Buy rating and $26 price target. Zevra has successfully launched Miplyffa for Niemann-Pick disease type C in the U.S. and the firm sees "multiple levers for further long term value creation," the analyst tells investors. Even with the success of Miplyffa in the U.S., the firm believes the stock "remains undervalued on the Miplyffa U.S. opportunity alone," the analyst added.
Citizens JMP
Jason Butler
Outperform
maintain
$18 -> $19
2025-05-14
Reason
Citizens JMP
Jason Butler
Price Target
$18 -> $19
2025-05-14
maintain
Outperform
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zevra Therapeutics Inc (ZVRA.O) is 18.50, compared to its 5-year average forward P/E of -5.49. For a more detailed relative valuation and DCF analysis to assess Zevra Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.49
Current PE
18.50
Overvalued PE
26.96
Undervalued PE
-37.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.77
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
22.58
Undervalued EV/EBITDA
-28.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.57
Current PS
0.00
Overvalued PS
16.98
Undervalued PS
2.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ZVRA News & Events

Events Timeline

(ET)
2025-12-02
07:40:00
Zevra Therapeutics Appoints Alicia Secor to Board of Directors
select
2025-11-20 (ET)
2025-11-20
16:09:35
Zevra Therapeutics Announces Departure of CFO R. LaDuane Clifton
select
2025-11-05 (ET)
2025-11-05
17:39:26
Zevra Therapeutics announces Q3 earnings per share of 1 cent, below consensus estimate of 2 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-03Benzinga
Key Stocks Reporting Earnings This Week: Joby, IonQ, AMD, and Others

  • Earnings Season Overview: Retail investors are gearing up for a busy week with over 1,600 companies reporting earnings, including notable names like Nvidia, Oracle, and Palantir Technologies.

  • Key Earnings Reports: Major companies reporting include FuboTV, BioCryst Pharmaceuticals, and Uber, with Palantir expected to show significant growth in AI platform demand.

  • Market Reactions: Investors are closely watching earnings from companies like Robinhood and McDonald's, with expectations for strong growth but potential volatility due to market conditions and regulatory changes.

  • Upcoming Reports: The week will also feature earnings from vaccine-makers Moderna and Novavax, as well as other companies like Airbnb and DraftKings, indicating a diverse range of sectors being analyzed.

[object Object]
Preview
5.0
10-10Yahoo Finance
Zevra Therapeutics (ZVRA): Assessing Valuation After Insider Purchases and Continued Revenue Increase

  • Insider Buying and Revenue Growth: Zevra Therapeutics (ZVRA) has attracted investor interest due to significant insider buying and steady revenue growth, with shares rising nearly 32% in the last month and 23.5% year-to-date, reflecting strong fundamentals and a favorable management sentiment.

  • Market Position and Future Potential: The company is well-positioned to capitalize on the growing prevalence of rare and neurodegenerative diseases, with its therapy MIPLYFFA showing promising patient uptake and retention, suggesting potential for continued revenue growth despite risks related to product adoption and clinical trial expansions.

[object Object]
Preview
5.0
10-07Newsfilter
Zevra Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • Zevra Therapeutics Grants Stock Options: Zevra Therapeutics, Inc. has granted options to purchase 38,000 shares of common stock to two new employees as part of its 2023 Employment Inducement Award Plan, with vesting occurring over four years.

  • Company Mission and Focus: Zevra is dedicated to developing therapies for rare diseases, utilizing data-driven strategies to address complex drug development challenges and improve treatment options for patients.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zevra Therapeutics Inc (ZVRA) stock price today?

The current price of ZVRA is 8.66 USD — it has decreased -0.69 % in the last trading day.

arrow icon

What is Zevra Therapeutics Inc (ZVRA)'s business?

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

arrow icon

What is the price predicton of ZVRA Stock?

Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24.00 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zevra Therapeutics Inc (ZVRA)'s revenue for the last quarter?

Zevra Therapeutics Inc revenue for the last quarter amounts to 26.06M USD, increased 605.36 % YoY.

arrow icon

What is Zevra Therapeutics Inc (ZVRA)'s earnings per share (EPS) for the last quarter?

Zevra Therapeutics Inc. EPS for the last quarter amounts to -0.01 USD, decreased -98.55 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zevra Therapeutics Inc (ZVRA)'s fundamentals?

The market is revising No Change the revenue expectations for Zevra Therapeutics, Inc. (ZVRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -3.24%.
arrow icon

How many employees does Zevra Therapeutics Inc (ZVRA). have?

Zevra Therapeutics Inc (ZVRA) has 59 emplpoyees as of December 05 2025.

arrow icon

What is Zevra Therapeutics Inc (ZVRA) market cap?

Today ZVRA has the market capitalization of 487.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free